Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Novel and conventional biomarkers for prediction of incident cardiovascular events in the community.

Melander, Olle LU orcid ; Newton-Cheh, Christopher ; Almgren, Peter LU ; Hedblad, Bo LU ; Berglund, Göran LU ; Engström, Gunnar LU ; Persson, Margaretha LU orcid ; Smith, Gustav LU ; Magnusson, Martin LU orcid and Christensson, Anders LU , et al. (2009) In JAMA: The Journal of the American Medical Association 302(1). p.49-57
Abstract
CONTEXT: Prior studies have demonstrated conflicting results regarding how much information novel biomarkers add to cardiovascular risk assessment. OBJECTIVE: To evaluate the utility of contemporary biomarkers for predicting cardiovascular risk when added to conventional risk factors. DESIGN, SETTING, AND PARTICIPANTS: Cohort study of 5067 participants (mean age, 58 years; 60% women) without cardiovascular disease from Malmö, Sweden, who attended a baseline examination between 1991 and 1994. Participants underwent measurement of C-reactive protein (CRP), cystatin C, lipoprotein-associated phospholipase 2, midregional proadrenomedullin (MR-proADM), midregional proatrial natriuretic peptide, and N-terminal pro-B-type natriuretic peptide... (More)
CONTEXT: Prior studies have demonstrated conflicting results regarding how much information novel biomarkers add to cardiovascular risk assessment. OBJECTIVE: To evaluate the utility of contemporary biomarkers for predicting cardiovascular risk when added to conventional risk factors. DESIGN, SETTING, AND PARTICIPANTS: Cohort study of 5067 participants (mean age, 58 years; 60% women) without cardiovascular disease from Malmö, Sweden, who attended a baseline examination between 1991 and 1994. Participants underwent measurement of C-reactive protein (CRP), cystatin C, lipoprotein-associated phospholipase 2, midregional proadrenomedullin (MR-proADM), midregional proatrial natriuretic peptide, and N-terminal pro-B-type natriuretic peptide (N-BNP) and underwent follow-up until 2006 using the Swedish national hospital discharge and cause-of-death registers and the Stroke in Malmö register for first cardiovascular events (myocardial infarction, stroke, coronary death). MAIN OUTCOME MEASURES: Incident cardiovascular and coronary events. RESULTS: During median follow-up of 12.8 years, there were 418 cardiovascular and 230 coronary events. Models with conventional risk factors had C statistics of 0.758 (95% confidence interval [CI], 0.734 to 0.781) and 0.760 (0.730 to 0.789) for cardiovascular and coronary events, respectively. Biomarkers retained in backward-elimination models were CRP and N-BNP for cardiovascular events and MR-proADM and N-BNP for coronary events, which increased the C statistic by 0.007 (P = .04) and 0.009 (P = .08), respectively. The proportion of participants reclassified was modest (8% for cardiovascular risk, 5% for coronary risk). Net reclassification improvement was nonsignificant for cardiovascular events (0.0%; 95% CI, -4.3% to 4.3%) and coronary events (4.7%; 95% CI, -0.76% to 10.1%). Greater improvements were observed in analyses restricted to intermediate-risk individuals (cardiovascular events: 7.4%; 95% CI, 0.7% to 14.1%; P = .03; coronary events: 14.6%; 95% CI, 5.0% to 24.2%; P = .003). However, correct reclassification was almost entirely confined to down-classification of individuals without events rather than up-classification of those with events. CONCLUSIONS: Selected biomarkers may be used to predict future cardiovascular events, but the gains over conventional risk factors are minimal. Risk classification improved in intermediate-risk individuals, mainly through the identification of those unlikely to develop events. (Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Cystatin C: blood, Cardiovascular Diseases: epidemiology, Cardiovascular Diseases: blood, C-Reactive Protein: metabolism, Biological Markers: blood, Adrenomedullin: blood, Atrial Natriuretic Factor: blood, Natriuretic Peptide, Brain: blood, Peptide Fragments: blood
in
JAMA: The Journal of the American Medical Association
volume
302
issue
1
pages
49 - 57
publisher
American Medical Association
external identifiers
  • wos:000267492800021
  • pmid:19567439
  • scopus:67649992452
  • pmid:19567439
ISSN
1538-3598
DOI
10.1001/jama.2009.943
language
English
LU publication?
yes
additional info
The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Hypertension and Cardiovascular Disease (013242540), Internal Medicine Research Unit (013242520), Cardio-vascular Epidemiology (013241610), Diabetes and Endocrinology (013241530), Emergency medicine/Medicine/Surgery (013240200)
id
874c2eb5-866a-4b12-95d5-0cf5584b834b (old id 1453482)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/19567439?dopt=Abstract
date added to LUP
2016-04-04 09:13:38
date last changed
2024-04-13 02:32:02
@article{874c2eb5-866a-4b12-95d5-0cf5584b834b,
  abstract     = {{CONTEXT: Prior studies have demonstrated conflicting results regarding how much information novel biomarkers add to cardiovascular risk assessment. OBJECTIVE: To evaluate the utility of contemporary biomarkers for predicting cardiovascular risk when added to conventional risk factors. DESIGN, SETTING, AND PARTICIPANTS: Cohort study of 5067 participants (mean age, 58 years; 60% women) without cardiovascular disease from Malmö, Sweden, who attended a baseline examination between 1991 and 1994. Participants underwent measurement of C-reactive protein (CRP), cystatin C, lipoprotein-associated phospholipase 2, midregional proadrenomedullin (MR-proADM), midregional proatrial natriuretic peptide, and N-terminal pro-B-type natriuretic peptide (N-BNP) and underwent follow-up until 2006 using the Swedish national hospital discharge and cause-of-death registers and the Stroke in Malmö register for first cardiovascular events (myocardial infarction, stroke, coronary death). MAIN OUTCOME MEASURES: Incident cardiovascular and coronary events. RESULTS: During median follow-up of 12.8 years, there were 418 cardiovascular and 230 coronary events. Models with conventional risk factors had C statistics of 0.758 (95% confidence interval [CI], 0.734 to 0.781) and 0.760 (0.730 to 0.789) for cardiovascular and coronary events, respectively. Biomarkers retained in backward-elimination models were CRP and N-BNP for cardiovascular events and MR-proADM and N-BNP for coronary events, which increased the C statistic by 0.007 (P = .04) and 0.009 (P = .08), respectively. The proportion of participants reclassified was modest (8% for cardiovascular risk, 5% for coronary risk). Net reclassification improvement was nonsignificant for cardiovascular events (0.0%; 95% CI, -4.3% to 4.3%) and coronary events (4.7%; 95% CI, -0.76% to 10.1%). Greater improvements were observed in analyses restricted to intermediate-risk individuals (cardiovascular events: 7.4%; 95% CI, 0.7% to 14.1%; P = .03; coronary events: 14.6%; 95% CI, 5.0% to 24.2%; P = .003). However, correct reclassification was almost entirely confined to down-classification of individuals without events rather than up-classification of those with events. CONCLUSIONS: Selected biomarkers may be used to predict future cardiovascular events, but the gains over conventional risk factors are minimal. Risk classification improved in intermediate-risk individuals, mainly through the identification of those unlikely to develop events.}},
  author       = {{Melander, Olle and Newton-Cheh, Christopher and Almgren, Peter and Hedblad, Bo and Berglund, Göran and Engström, Gunnar and Persson, Margaretha and Smith, Gustav and Magnusson, Martin and Christensson, Anders and Struck, Joachim and Morgenthaler, Nils G and Bergmann, Andreas and Pencina, Michael J and Wang, Thomas J}},
  issn         = {{1538-3598}},
  keywords     = {{Cystatin C: blood; Cardiovascular Diseases: epidemiology; Cardiovascular Diseases: blood; C-Reactive Protein: metabolism; Biological Markers: blood; Adrenomedullin: blood; Atrial Natriuretic Factor: blood; Natriuretic Peptide; Brain: blood; Peptide Fragments: blood}},
  language     = {{eng}},
  number       = {{1}},
  pages        = {{49--57}},
  publisher    = {{American Medical Association}},
  series       = {{JAMA: The Journal of the American Medical Association}},
  title        = {{Novel and conventional biomarkers for prediction of incident cardiovascular events in the community.}},
  url          = {{http://dx.doi.org/10.1001/jama.2009.943}},
  doi          = {{10.1001/jama.2009.943}},
  volume       = {{302}},
  year         = {{2009}},
}